NEOG · Neogen Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '24 | Q2 '24 | Q3 '24 | Q2 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $211.20M | $224.69M | $209.19M | $231.26M | $220.98M | $216.96M | $229.63M | $228.81M | $230.03M | $218.25M |
| Cost of Revenue | $112.20M | $118.01M | $114.22M | $117.93M | $110.72M | $112.04M | $112.86M | $111.93M | $117.49M | $110.29M |
| Gross Profit | $99.00M | $106.68M | $94.97M | $113.33M | $110.27M | $104.93M | $116.77M | $116.88M | $112.54M | $107.96M |
| R&D | $3.80M | $4.56M | $5.13M | $5.11M | $4.47M | $5.20M | $5.76M | $4.85M | $6.85M | $7.26M |
| SG&A | $60.30M | $65.21M | $60.89M | $57.77M | $55.78M | $51.67M | $51.72M | $52.09M | $77.00M | $46.42M |
| Total Operating Expenses | $102.30M | $112.06M | $111.06M | $570.81M | $104.85M | $102.67M | $102.31M | $104.86M | $120.19M | $92.28M |
| D&A | - | - | $29.05M | - | - | $29.80M | - | - | - | - |
| Operating Income | ($3.30M) | ($5.38M) | ($16.09M) | ($457.48M) | $5.42M | $2.26M | $14.46M | $12.02M | ($7.66M) | $15.68M |
| Interest Expense | - | - | - | - | - | $10.60M | $8.33M | $10.50M | $11.00M | $9.10M |
| Income Tax | ($3.30M) | ($4.44M) | $7.47M | ($20.29M) | $1.23M | ($3.00M) | ($260.0K) | ($3.80M) | $7.75M | ($10.45M) |
| Net Income | ($17.00M) | ($15.92M) | $36.34M | ($456.28M) | ($10.96M) | ($12.61M) | ($3.49M) | ($2.02M) | ($41.84M) | $8.19M |
| EPS - Basic | ($0.08) | ($0.07) | $0.17 | ($2.10) | ($0.05) | ($0.06) | ($0.02) | ($0.01) | ($0.19) | $0.04 |
| EPS - Diluted | ($0.08) | ($0.07) | $0.17 | ($2.10) | ($0.05) | ($0.06) | ($0.02) | ($0.01) | ($0.19) | $0.04 |
Balance Sheet
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '24 | Q2 '24 | Q3 '24 | Q2 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $159.90M | $145.34M | $138.88M | $129.00M | $127.70M | $120.48M | $170.61M | $161.44M | $163.24M | $67.13M |
| Accounts Receivable | $137.10M | $132.00M | $138.46M | $153.38M | $160.07M | $167.64M | $173.00M | $173.59M | $153.25M | $146.39M |
| Inventory | $161.70M | $162.77M | $193.41M | $190.86M | $205.44M | $198.60M | $189.27M | $182.39M | $133.81M | $143.86M |
| Accounts Payable | $75.20M | $63.04M | $76.60M | $79.61M | $72.24M | $61.46M | $83.06M | $89.75M | $76.67M | $60.49M |
| Current Assets | $590.00M | $574.58M | $524.06M | $576.94M | $551.71M | $540.65M | $589.23M | $602.47M | $585.93M | $555.37M |
| Total Assets | $3.36B | $3.36B | $3.38B | $3.44B | $4.04B | $4.50B | $4.55B | $4.58B | $4.55B | $4.51B |
| Current Liabilities | $150.60M | $147.05M | $146.21M | $174.01M | $141.20M | $122.69M | $154.32M | $157.84M | $145.47M | $107.16M |
| Long-term Debt | $793.30M | $792.93M | $792.53M | $874.81M | $890.61M | $889.13M | $888.39M | $887.65M | $885.44M | $884.70M |
| Total Liabilities | $1.26B | $1.26B | $1.26B | $1.37B | $1.38B | $1.37B | $1.40B | $1.44B | $1.42B | $1.38B |
| Stockholders' Equity | $2.10B | $2.10B | $2.12B | $2.07B | $2.66B | $3.14B | $3.14B | $3.15B | $3.13B | $3.13B |
| Retained Earnings | ($533.00M) | ($516.01M) | ($500.09M) | ($536.42M) | $75.77M | $543.01M | $555.62M | $561.03M | $565.04M | $559.47M |
Cash Flow
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '24 | Q2 '24 | Q3 '24 | Q2 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | $10.85M | - | - | ($17.91M) | - | - | - | - |
| Investing Cash Flow | - | - | $97.72M | - | - | ($33.66M) | - | - | - | - |
| Financing Cash Flow | - | - | ($99.39M) | - | - | $979.0K | - | - | - | - |
| CapEx | - | - | $24.00M | - | - | $38.43M | - | - | - | - |
| Free Cash Flow | - | - | ($13.15M) | - | - | ($56.35M) | - | - | - | - |
Ratios
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '24 | Q2 '24 | Q3 '24 | Q2 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 46.9% | 47.5% | 45.4% | 49.0% | 49.9% | 48.4% | 50.9% | 51.1% | 48.9% | 49.5% |
| Operating margin | -1.6% | -2.4% | -7.7% | -197.8% | 2.5% | 1.0% | 6.3% | 5.3% | -3.3% | 7.2% |
| EBITDA margin | - | - | 6.2% | - | - | 14.8% | - | - | - | - |
| Net margin | -8.0% | -7.1% | 17.4% | -197.3% | -5.0% | -5.8% | -1.5% | -0.9% | -18.2% | 3.8% |
| Free cash flow margin | - | - | -6.3% | - | - | -26.0% | - | - | - | - |
| FCF / Net income | - | - | -0.36 | - | - | 4.47 | - | - | - | - |
| R&D / Revenue | 1.8% | 2.0% | 2.4% | 2.2% | 2.0% | 2.4% | 2.5% | 2.1% | 3.0% | 3.3% |
| SG&A / Revenue | 28.6% | 29.0% | 29.1% | 25.0% | 25.2% | 23.8% | 22.5% | 22.8% | 33.5% | 21.3% |
| Effective tax rate | - | - | 17.1% | - | - | - | - | - | - | - |
| Return on assets | -0.5% | -0.5% | 1.1% | -13.2% | -0.3% | -0.3% | -0.1% | -0.0% | -0.9% | 0.2% |
| Return on equity | -0.8% | -0.8% | 1.7% | -22.0% | -0.4% | -0.4% | -0.1% | -0.1% | -1.3% | 0.3% |
| Return on invested capital | -0.1% | -0.1% | -0.5% | -12.3% | 0.1% | 0.0% | 0.3% | 0.2% | -0.2% | 0.3% |
| Liquidity | ||||||||||
| Current ratio | 3.92 | 3.91 | 3.58 | 3.32 | 3.91 | 4.41 | 3.82 | 3.82 | 4.03 | 5.18 |
| Quick ratio | 2.84 | 2.80 | 2.26 | 2.22 | 2.45 | 2.79 | 2.59 | 2.66 | 3.11 | 3.84 |
| Cash ratio | 1.06 | 0.99 | 0.95 | 0.74 | 0.90 | 0.98 | 1.11 | 1.02 | 1.12 | 0.63 |
| Leverage | ||||||||||
| Debt / Equity | 0.38 | 0.38 | 0.37 | 0.42 | 0.33 | 0.28 | 0.28 | 0.28 | 0.28 | 0.28 |
| Debt / Assets | 0.24 | 0.24 | 0.23 | 0.25 | 0.22 | 0.20 | 0.20 | 0.19 | 0.19 | 0.20 |
| Debt / EBITDA | - | - | 61.13 | - | - | 27.74 | - | - | - | - |
| Interest coverage | - | - | - | - | - | 0.2x | 1.7x | 1.1x | -0.7x | 1.7x |
| Equity multiplier | 1.60 | 1.60 | 1.59 | 1.66 | 1.52 | 1.44 | 1.45 | 1.46 | 1.45 | 1.44 |
| Liabilities / Assets | 0.37 | 0.37 | 0.37 | 0.40 | 0.34 | 0.30 | 0.31 | 0.31 | 0.31 | 0.31 |
| Efficiency | ||||||||||
| Asset turnover | 0.06 | 0.07 | 0.06 | 0.07 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 |
| Inventory turnover | 0.69 | 0.73 | 0.59 | 0.62 | 0.54 | 0.56 | 0.60 | 0.61 | 0.88 | 0.77 |
| Days sales outstanding | 237d | 214d | 242d | 242d | 264d | 282d | 275d | 277d | 243d | 245d |
| Days inventory outstanding | 526d | 503d | 618d | 591d | 677d | 647d | 612d | 595d | 416d | 476d |
| Days payable outstanding | 245d | 195d | 245d | 246d | 238d | 200d | 269d | 293d | 238d | 200d |
| Cash conversion cycle | 518d | 523d | 615d | 586d | 704d | 729d | 618d | 579d | 421d | 521d |
| Valuation | ||||||||||
| P / E | - | - | 33.8x | - | - | - | - | - | - | 442.3x |
| P / B | 1.2x | 0.6x | 0.6x | 0.6x | 0.8x | 1.2x | 0.9x | 1.2x | 1.2x | 1.2x |
| P / S | 11.6x | 5.8x | 6.0x | 5.5x | 9.9x | 17.2x | 12.4x | 16.3x | 16.4x | 17.5x |
| EV / EBITDA | - | - | 146.8x | - | - | 140.6x | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -4.4% | -2.8% | - | 0.7% | -3.4% | 63.9% | -0.2% | 4.8% | 76.2% | 70.2% |
| Revenue CAGR (3y) | -1.1% | -0.8% | 16.5% | 21.0% | 19.9% | - | 25.9% | 25.2% | 29.0% | 29.8% |
| Revenue CAGR (5y) | 12.6% | 14.3% | - | 16.6% | 17.2% | 16.8% | 17.9% | 18.6% | 17.7% | 17.9% |
| Gross profit growth (YoY) | -10.2% | -5.9% | - | -2.9% | -5.7% | 68.5% | 3.8% | 8.3% | 85.7% | 88.1% |
| Operating income growth (YoY) | - | 98.8% | - | - | -55.0% | -62.8% | - | -23.3% | - | 145.9% |
| Net income growth (YoY) | -55.2% | 96.5% | - | -12985.2% | -441.9% | - | 91.7% | - | - | 50.5% |
| EPS growth (YoY) | -60.0% | 96.7% | - | -10400.0% | -400.0% | - | 89.5% | - | - | -20.0% |
| EPS CAGR (3y) | - | - | 50.4% | - | - | - | - | - | - | -44.2% |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | -34.0% |
| FCF growth (YoY) | - | - | - | - | - | -107.6% | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -21.0% | 1.6% | - | -34.1% | -15.4% | 254.7% | 0.3% | 0.7% | 253.2% | 257.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-05-31.
Business segments
$894.66M totalFood Safety$638.14M · 71.3%
Animal Safety$256.52M · 28.7%
Product / service
$1.64B totalProduct$797.32M · 48.8%
Indicator Testing Culture Media And Other$325.92M · 19.9%
Bacterial And General Sanitation$164.78M · 10.1%
Service$97.35M · 6.0%
Natural Toxins And Allergens$77.06M · 4.7%
Veterinary Instruments And Disposables$61.47M · 3.8%
Rodenticides Insecticides And Disinfectants$46.97M · 2.9%
Animal Care And Other$34.65M · 2.1%
Genomics Services$23.42M · 1.4%
Life Sciences$6.50M · 0.4%
Geographic
$894.66M totalNon Us$448.73M · 50.2%
US$445.94M · 49.8%
Peer comparison
Same SIC group: In Vitro & In Vivo Diagnostic Substances
Comparing NEOGEN CORP against the 5 most active filers in the same SIC group.